Collegium Pharmaceutical Revenue and Competitors

Boston, MA USA

Location

$106M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Collegium Pharmaceutical's estimated annual revenue is currently $325.8M per year.(i)
  • Collegium Pharmaceutical's estimated revenue per employee is $1,374,599
  • Collegium Pharmaceutical's total funding is $106M.
  • Collegium Pharmaceutical's current valuation is $649.1M. (January 2022)

Employee Data

  • Collegium Pharmaceutical has 237 Employees.(i)
  • Collegium Pharmaceutical grew their employee count by -1% last year.

Collegium Pharmaceutical's People

NameTitleEmail/Phone
1
EVP, Head Technical OperationsReveal Email/Phone
2
EVP, General Counsel & Chief Administrative OfficerReveal Email/Phone
3
HEAD OF STRATEGY AND CORPORATE DEVELOPMENTReveal Email/Phone
4
VP, Corporate CommunicationsReveal Email/Phone
5
VP, Commercial OperationsReveal Email/Phone
6
HEAD OF HUMAN RESOURCESReveal Email/Phone
7
VP FinanceReveal Email/Phone
8
VP, Market Access & TradeReveal Email/Phone
9
VP, Clinical OperationsReveal Email/Phone
10
ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is Collegium Pharmaceutical?

Collegium Pharmaceutical, Inc., is a privately held pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products for the rapidly growing reformulation market and related areas. The Company's products target market opportunities through product improvement and line extension strategies protected by intellectual property (IP), creating a portfolio of improved pharmaceutical products. Collegium uses its broad expertise in IP development, drug formulation, manufacturing, basic science (chemistry, biology, bioengineering), marketing and clinical trials management to identify and execute product opportunities across multiple therapeutic areas.

keywords:N/A

$106M

Total Funding

237

Number of Employees

$325.8M

Revenue (est)

-1%

Employee Growth %

$649.1M

Valuation

N/A

Accelerator

Collegium Pharmaceutical News

2022-04-17 - Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by Zacks ...

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio...

2022-04-13 - Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $31.00 ...

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio...

2022-03-30 - Collegium Pharmaceutical sees 65% growth in product revenue post BioDelivery acquisition: 2022 Guidance

Collegium Pharmaceutical sees 65% growth in product revenue post BioDelivery acquisition: 2022 Guidance. Apr. 05, 2022 8:38 AM ETCollegium Pharmaceutical,...

2021-08-16 - Collegium Pharmaceutical : Announces $100 Million Share Repurchase Program

STOUGHTON, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that its Board of Directors has authorized the repurchase of up to $100 million of t ...

2017-11-22 - A scrappy upstart in the pain pill business takes on mighty Purdue Pharma

CANTON, Mass. — Collegium Pharmaceutical, the scrappy upstart taking on the mighty opioid maker Purdue Pharma, is having a moment. The company recently convinced Cigna, Humana, Navitus, and top health insurers in Florida and Pennsylvania to cover only its product Xtampza — and not Purdue’s infa ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$61.7M2472%N/A
#2
$49.1M2488%N/A
#3
$66.9M2547%N/A
#4
$66.9M2686%N/A
#5
$51.2M3410%N/A